glp-1 agonist side effects Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, effects, and risks Gastrointestinal effect and adverse effects

Pinealon: A brain-directed peptide complex studied for its potential role in supporting neuroendocrine function and maintaining cognitive performance under stress

Conclusion In recent years, clinical guidelines have begun to emphasize the importance of diabetes-related NDs and their risk of cognitive impairment, despite widespread concerns

Cell Death Differ 28:11351148

Nourishing Formula: Beaute Melasma-X is more than just a tone-up cream

doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update